Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Answers to complex questions cannot be derived from "simple" trials.

Literature DB >> 1449915

Answers to complex questions cannot be derived from "simple" trials.

E J Topol¹, R M Califf.

Abstract

Mesh：

Year: 1992 PMID： 1449915 PMCID： PMC1025130 DOI： 10.1136/hrt.68.10.348

Source DB: PubMed Journal: Br Heart J ISSN： 0007-0769

× No keyword cloud information.

10 in total

1. GISSI-2: mortality plus extensive left-ventricular damage as "end-point".

Authors: C De Vita; M G Franzosi; E Geraci; A P Maggioni; F Mauri; G Mezzanotte; L Tavazzi; G Tognoni; A Volpi
Journal: Lancet Date: 1990-02-03 Impact factor: 79.321

2. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.

Authors: E J Topol; R M Califf; B S George; D J Kereiakes; D Rothbaum; R J Candela; C W Abbotsmith; C A Pinkerton; D C Stump; D Collen
Journal: Circulation Date: 1988-05 Impact factor: 29.690

Review 3. Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials.

Authors: R M Califf; L Harrelson-Woodlief; E J Topol
Journal: Circulation Date: 1990-11 Impact factor: 29.690

4. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis.

Authors: M B Honan; F E Harrell; K A Reimer; R M Califf; D B Mark; D B Pryor; M A Hlatky
Journal: J Am Coll Cardiol Date: 1990-08 Impact factor: 24.094

5. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group.

Authors: R M Califf; E J Topol; R S Stack; S G Ellis; B S George; D J Kereiakes; J K Samaha; S J Worley; J L Anderson; L Harrelson-Woodlief
Journal: Circulation Date: 1991-05 Impact factor: 29.690

6. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.

Authors: E J Topol; R M Califf; B S George; D J Kereiakes; C W Abbottsmith; R J Candela; K L Lee; B Pitt; R S Stack; W W O'Neill
Journal: N Engl J Med Date: 1987-09-03 Impact factor: 91.245

7. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator.

Authors: M Verstraete; R Bernard; M Bory; R W Brower; D Collen; D P de Bono; R Erbel; W Huhmann; R J Lennane; J Lubsen
Journal: Lancet Date: 1985-04-13 Impact factor: 79.321

8. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.

Authors: M L Simoons; A E Arnold; A Betriu; D P de Bono; J Col; F C Dougherty; R von Essen; H Lambertz; J Lubsen; B Meier
Journal: Lancet Date: 1988-01-30 Impact factor: 79.321

9. Difference between herpes simplex virus type 1 and type 2 neonatal encephalitis in neurological outcome.

Authors: L Corey; R J Whitley; E F Stone; K Mohan
Journal: Lancet Date: 1988 Jan 2-9 Impact factor: 79.321

Review 10. Coronary angioplasty for acute myocardial infarction.

Authors: E J Topol
Journal: Ann Intern Med Date: 1988-12-15 Impact factor: 25.391